Scientists at St. Jude Children's Research Hospital in Memphis have identified a gene that pushes the immune system's cancer-killing T cells into a worn-out state, a major obstacle for immunotherapy. In mouse experiments published in Nature, deleting the gene, ZMYND8, from CD8+ T cells improved control of melanoma and chronic viral infection. Combining the deletion with existing immunotherapy approaches improved survival further.
The work speaks to a hard problem for families of children with cancer. Immunotherapy has improved survival for some adults and children, but it has had limited success against many pediatric solid tumors, partly because T cells become exhausted after long exposure to disease. The research is at the laboratory stage. No patients were treated, and no drug was tested.
Inside the Mouse Experiments
T cells normally attack infected or cancerous cells, but constant stimulation from a tumor or a lasting infection can wear them down. Using single-cell CRISPR screening, which removes genes one at a time and tracks the effect cell by cell, the team found that ZMYND8 acts as a master regulator of that exhaustion, Medical Xpress reported.
The researchers traced the mechanism to a molecular brake. According to the St. Jude announcement, ZMYND8 binds to and suppresses p300, a protein that switches on the gene for the interleukin-2 (IL-2) receptor. With that receptor turned down, T cells respond poorly to IL-2, a key activation signal.
When the team deleted the gene in mice, T cells stayed more functional. Combining the deletion with checkpoint blockade, a type of immunotherapy that stops cancer from hiding from the immune system, or with IL-2 further improved survival. Hongbo Chi, PhD, chair of St. Jude's Department of Immunology, said the results suggest "we may have a new therapeutic target to explore to improve these therapies."
Promising Biology at an Early Stage
This is a mouse and laboratory study published in a peer-reviewed journal. The disease models were melanoma and chronic viral infection, not childhood tumors. Deleting a gene in engineered mice is very different from developing a medicine that could safely block ZMYND8 in people, and no such drug exists.
The finding builds on other St. Jude research into why T cells tire out. A 2021 St. Jude study used samples from a pediatric CAR T-cell trial to examine why the therapy's effect wanes over time, weighing whether T-cell exhaustion or loss of the cells limits response. Several genetic switches appear to steer T cells toward exhaustion, and researchers are still sorting out which ones can be targeted safely.
Current treatment guidance has not changed. Checkpoint inhibitors and cell therapies remain options only for specific cancers, and the new work does not predict which patients might benefit from a future ZMYND8-based approach.
What Families Weighing Immunotherapy Can Do
Children with solid tumors and their families have the most at stake, along with adults whose cancers stop responding to checkpoint drugs. The improved control of chronic viral infection in mice also suggests the pathway may matter beyond cancer. None of these groups should expect a new treatment soon.
Families can still act on what exists today. Ask the care team whether immunotherapy is standard for the specific diagnosis and whether a clinical trial is open. Trials are listed on ClinicalTrials.gov, and large pediatric cancer centers can review eligibility. Be wary of clinics or online sellers promising immune-boosting treatments outside regulated trials.
Cost and distance are real barriers because specialized trials are concentrated at major centers. Families should ask early whether the hospital's social workers can help with travel, lodging, and insurance questions, and keep copies of pathology reports and treatment records ready for any second opinion.
St. Jude says treatments developed there helped raise the overall childhood cancer survival rate from 20% to more than 80% since the hospital opened more than 60 years ago. The next questions are whether ZMYND8 can be blocked with a drug, whether the effect holds in human T cells and pediatric tumor models, and whether doing so is safe.
Key Questions Answered
What did St. Jude scientists discover? They found that the gene ZMYND8 drives CD8+ T-cell exhaustion. Deleting it improved T-cell function in mice.
Was this tested in children? No. The experiments used mouse models of melanoma and chronic viral infection.
Does this change cancer treatment now? No. No therapy targeting ZMYND8 exists, and treatment guidance has not changed.
Why does T-cell exhaustion matter? Exhausted T cells lose much of their ability to attack tumors. It is one reason immunotherapy often fails against pediatric solid tumors.
How did the deletion work with immunotherapy? Combined with checkpoint blockade or IL-2, it further improved survival in mice. Human studies are still needed.
Where can families find clinical trials? ClinicalTrials.gov lists open studies, and pediatric cancer centers can help review eligibility.
Published by Medicaldaily.com
